Acotec Scientific Holdings Ltd. is a medical device technology platform company, which engages in research and development on providing treatment solutions for vascular diseases. The company is headquartered in Beijing, Beijing and currently employs 645 full-time employees. The company went IPO on 2021-08-24. The firm is primarily engaged in the research and development on providing treatment solutions for vascular diseases, involving drug-coated balloons (DCB) and percutaneous transluminal angioplasty balloon catheters (PTA). The Company’s main products include AcoArt Orchid & Dhalia, AcoArt Tulip & Litos, AcoArt Iris & Jasmin, AcoArt Lily & Rosmarin, Peripheral Aspiration System (AcoStream), Radiofrequency Ablation System (AcoArt Cedar), 2nd Gen Peripheral Aspiration System (2nd Generation AcoStream) and others, covering fields such as vascular surgery, cardiology, nephrology and neurology. The firm conducts businesses within domestic and overseas markets.